Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

EXEL.com" target="_new">http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Compan
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... HILL, N.C. , Aug. 28, 2015 /PRNewswire/ ... market research projects can slow down the decision-making ... It is, therefore, absolutely critical for biopharmaceutical companies ... market research approval process for quicker and more ... research by Best Practices, LLC, nearly three-quarters of ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Originally discovered by ... Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, ... Senju Pharmaceutical Co., Ltd under the trade name ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:8/31/2015)... ... August 31, 2015 , ... The ... on the use of health IT to create efficiencies in healthcare information exchange, ... 2015 . Taking place at the Hyatt Regency Reston in Reston, Va. from ...
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like ... director of GreenFields of Geneva. During his first days on the job, he’s run ... nice seeing them, and I like knowing that they’re living in such a wonderful ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Brooks Group, a global ... a department devoted to helping organizations identify and keep the best talent both ... The Brooks Group believes in offering a solution that goes beyond simply providing ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech ... Business Owners and provided a tour of their North American facility following the ... to international companies expanding business in the U.S. , The PartnerTech Inc. ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... According to ... Cancer Solution: Taking Charge of Your Life with Cancer is an excellent resource ... Santangeloon found The Cancer Solution to be helpful in explaining what cancer is in ...
Breaking Medicine News(10 mins):Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:PartnerTech Supports Economic Growth as Host 2Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2
... education bill in the state that allows private professional colleges ... ,Lok Sabha member Panniyan Ravindran, while talking to the Gulf ... said he would fight it. ,He was in ... anniversary of Kerala's former chief minister P.K. Vasudevan Nair. ...
... Bhopal and two of its doctors have been asked by ... for alleged// post-operative negligence resulting in the death of a ... Ayushman Hospital following swelling in her uterus and respiratory trouble. ... Since the tumor was not malignant and the possibility of ...
... Health Organization has communicated to countries the benefits of building ... 100 companies have sent in their request// to Roche AG, ... to combat a potential bird-flu pandemic. ,Though ... flu, yet they have enabled companies a list of things ...
... Health Canada has warned about the inherent risks involved ... ,The human milk is capable of ... There are chances that the human milk carries remnants ... consumed. Even unhygienic storage of milk, and not adhering ...
... care workers in the United States has risen, so ... ,According to Vanderbilt infectious disease experts Timothy ... should be provided to health care workers with latent ... test, particularly if they meet certain high-risk criteria. ...
... Pharma company Venus Remedies Ltd today said it ... its latest antibiotic fixed dose combination used in ... ,The new antibiotic combination, active against multi-resistant strains ... provides a broad-spectrum coverage of bactericidal activity, it ...
Cached Medicine News:
VACUETTE® Tube Holders should be used exclusively with VACUETTE® Blood Collection Needles as both components are designed for optimal compatibility with one another....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Less traumatic jaws offer a firm grasp while a self-retaining spring maintains hold on the needle. Use for grasping, applying endoloops, and driving needles during extracorporeal suturing....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: